Display options
Cite
Singh N, Tripathi AK, Sahu DK, et al. Differential genomics and transcriptomics between tyrosine kinase inhibitor-sensitive and -resistant BCR-ABL-dependent chronic myeloid leukemia. Oncotarget. 2018;9(54):30385-30418doi: 10.18632/oncotarget.25752.
Singh, N., Tripathi, A. K., Sahu, D. K., Mishra, A., Linan, M., Argente, B., Varkey, J., Parida, N., Chowdhry, R., Shyam, H., Alam, N., Dixit, S., Shankar, P., Mishra, A., Agarwal, A., Yoo, C., Bhatt, M. L. B., & Kant, R. (2018). Differential genomics and transcriptomics between tyrosine kinase inhibitor-sensitive and -resistant BCR-ABL-dependent chronic myeloid leukemia. Oncotarget, 9(54), 30385-30418. https://doi.org/10.18632/oncotarget.25752
Singh, Neetu, et al. "Differential genomics and transcriptomics between tyrosine kinase inhibitor-sensitive and -resistant BCR-ABL-dependent chronic myeloid leukemia." Oncotarget vol. 9,54 (2018): 30385-30418. doi: https://doi.org/10.18632/oncotarget.25752
Singh N, Tripathi AK, Sahu DK, Mishra A, Linan M, Argente B, Varkey J, Parida N, Chowdhry R, Shyam H, Alam N, Dixit S, Shankar P, Mishra A, Agarwal A, Yoo C, Bhatt MLB, Kant R. Differential genomics and transcriptomics between tyrosine kinase inhibitor-sensitive and -resistant BCR-ABL-dependent chronic myeloid leukemia. Oncotarget. 2018 Jul 13;9(54):30385-30418. doi: 10.18632/oncotarget.25752. eCollection 2018 Jul 13. PMID: 30100996; PMCID: PMC6084383.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2018 Jul 13;9(54):30385-30418. doi: 10.18632/oncotarget.25752. eCollection 2018 Jul 13.

Differential genomics and transcriptomics between tyrosine kinase inhibitor-sensitive and -resistant BCR-ABL-dependent chronic myeloid leukemia.

Oncotarget

Neetu Singh, Anil Kumar Tripathi, Dinesh Kumar Sahu, Archana Mishra, Margaret Linan, Bianca Argente, Julia Varkey, Niranjan Parida, Rebecca Chowdhry, Hari Shyam, Nawazish Alam, Shivani Dixit, Pratap Shankar, Abhishek Mishra, Avinash Agarwal, Chris Yoo, Madan Lal Brahma Bhatt, Ravi Kant

Affiliations

  1. Molecular Biology Unit, Center for Advance Research, King George's Medical University, Lucknow, India.
  2. Department of Clinical Hematology, King George's Medical University, Lucknow, India.
  3. Department of Cardio Thoracic and Vascular Surgery, King George's Medical University, Lucknow, India.
  4. Systems Imagination, Scottsdale, Arizona, USA.
  5. Department of Periodontics, King George's Medical University, Lucknow, India.
  6. Department of Medicine, King George's Medical University, Lucknow, India.
  7. Department of Radiotherapy, King George's Medical University, Lucknow, India.
  8. All India Institute of Medical Sciences, Rishikesh, India.

PMID: 30100996 PMCID: PMC6084383 DOI: 10.18632/oncotarget.25752

Abstract

Previously, it has been stated that the BCR-ABL fusion-protein is sufficient to induce Chronic Myeloid Leukemia (CML), but additional genomic-changes are required for disease progression. Hence, we profiled control and tyrosine kinase inhibitors (TKI) alone or in combination with other drug-treated CML-samples in different phases, categorized as drug-sensitive and drug-resistant on the basis of BCR-ABL transcripts, the marker of major molecular-response. Molecular-profiling was done using the molecular-inversion probe-based-array, Human Transcriptomics-Array2.0, and Axiom-Biobank genotyping-arrays. At the transcript-level, clusters of control, TKI-resistant and TKI-sensitive cases were correlated with BCR-ABL transcript-levels. Both at the gene- and exon-levels, up-regulation of MPO, TPX2, and TYMS and down-regulation of STAT6, FOS, TGFBR2, and ITK lead up-regulation of the cell-cycle, DNA-replication, DNA-repair pathways and down-regulation of the immune-system, chemokine- and interleukin-signaling, TCR, TGF beta and MAPK signaling pathways. A comparison between TKI-sensitive and TKI-resistant cases revealed up-regulation of LAPTM4B, HLTF, PIEZO2, CFH, CD109, ANGPT1 in CML-resistant cases, leading to up-regulation of autophagy-, protein-ubiquitination-, stem-cell-, complement-, TGFβ- and homeostasis-pathways with specific involvement of the Tie2 and Basigin signaling-pathway. Dysregulated pathways were accompanied with low CNVs in CP-new and CP-UT-TKI-sensitive-cases with undetectable BCR-ABL-copies. High CNVs (previously reported gain of 9q34) were observed in BCR-ABL-independent and -dependent TKI, non-sensitive-CP-UT/AP-UT/B-UT and B-new samples. Further, genotyping CML-CP-UT cases with BCR-ABL 0-to-77.02%-copies, the identified, rsID239798 and rsID9475077, were associated with FAM83B, a candidate for therapeutic resistance. The presence of BCR-ABL, additional genetic-events, dysregulated-signaling-pathways and rsIDs associated with FAM83B in TKI-resistant-cases can be used to develop a signature-profile that may help in monitoring therapy.

Keywords: axiom biobank array; chronic myeloid leukemia; human-transcriptome array 2.0; molecular-inversion-probe based array; tyrosine kinase inhibitors

Conflict of interest statement

CONFLICTS OF INTEREST The authors also declare no conflicts of interest.

References

  1. Cancer Metastasis Rev. 2000;19(1-2):13-7 - PubMed
  2. Front Genet. 2016 Jun 13;7:105 - PubMed
  3. J Cancer Res Clin Oncol. 2013 Apr;139(4):661-7 - PubMed
  4. Genomics. 2013 Oct;102(4):250-6 - PubMed
  5. Oncotarget. 2013 May;4(5):715-28 - PubMed
  6. Clin Adv Hematol Oncol. 2014 Jul;12(7 Suppl 13):3-17, 1 - PubMed
  7. Int J Hematol. 2011 Apr;93(4):465-473 - PubMed
  8. J Biol Chem. 2009 Feb 27;284(9):5497-505 - PubMed
  9. J Mol Diagn. 2013 Sep;15(5):556-64 - PubMed
  10. IUBMB Life. 2009 Aug;61(8):800-30 - PubMed
  11. Clin Cancer Res. 2009 May 15;15(10):3442-50 - PubMed
  12. Cancer Genet. 2012 Sep;205(9):465-9 - PubMed
  13. Int J Biomed Sci. 2013 Mar;9(1):48-53 - PubMed
  14. Autophagy. 2017;13(12):2056-2071 - PubMed
  15. Oncogene. 2016 Dec 15;35(50):6359-6365 - PubMed
  16. J Invest Dermatol. 2014 Feb;134(2):498-506 - PubMed
  17. Oncogene. 2014 Jun 19;33(25):3298-306 - PubMed
  18. Cell Mol Life Sci. 2017 May;74(9):1605-1624 - PubMed
  19. J Clin Invest. 2012 Sep;122(9):3197-210 - PubMed
  20. Cancer Med. 2017 Dec;6(12):2942-2956 - PubMed
  21. Cancer Lett. 2016 Mar 1;372(1):24-35 - PubMed
  22. Leukemia. 2016 Sep;30(9):1861-8 - PubMed
  23. Genome Res. 2004 Oct;14(10B):2121-7 - PubMed
  24. Leukemia. 2014 Aug;28(8):1745-7 - PubMed
  25. Front Microbiol. 2017 Nov 15;8:2244 - PubMed
  26. J Biol Chem. 2011 Jan 21;286(3):2236-44 - PubMed
  27. Blood. 2010 Jan 14;115(2):315-25 - PubMed
  28. Histopathology. 2011 May;58(6):984-8 - PubMed
  29. Genes Chromosomes Cancer. 2006 May;45(5):482-94 - PubMed
  30. Stem Cell Res. 2015 Nov;15(3):678-693 - PubMed
  31. Gene. 2015 Jul 10;565(2):295-308 - PubMed
  32. Blood. 2013 Aug 8;122(6):872-84 - PubMed
  33. Matrix Biol. 2001 Sep;20(5-6):319-25 - PubMed
  34. Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2794-9 - PubMed
  35. Nat Med. 2010 Feb;16(2):214-8 - PubMed
  36. Gene. 2016 Feb 1;576(2 Pt 2):734-42 - PubMed
  37. J Clin Oncol. 2014 Feb 10;32(5):415-23 - PubMed
  38. Oncotarget. 2013 May;4(5):729-38 - PubMed
  39. BMC Genomics. 2010 Jan 18;11:41 - PubMed
  40. N Engl J Med. 2009 Jan 29;360(5):470-80 - PubMed
  41. J Clin Invest. 2012 Sep;122(9):3048-51 - PubMed
  42. Leuk Lymphoma. 2008 Jan;49(1):19-26 - PubMed
  43. Br J Haematol. 2014 Jul;166(2):250-3 - PubMed
  44. Genes Chromosomes Cancer. 2007 Nov;46(11):1039-50 - PubMed
  45. Biochim Biophys Acta. 2011 May;1813(5):742-53 - PubMed
  46. Genomics. 2011 Aug;98(2):79-89 - PubMed
  47. Virchows Arch. 2008 Nov;453(5):491-9 - PubMed
  48. Bull Exp Biol Med. 2016 Aug;161(4):495-500 - PubMed
  49. Sheng Li Xue Bao. 2007 Aug 25;59(4):517-23 - PubMed
  50. Oncologist. 2016 May;21(5):626-33 - PubMed
  51. Trends Cell Biol. 2016 May;26(5):352-366 - PubMed
  52. Genomics. 2011 Dec;98(6):422-30 - PubMed

Publication Types